Peginesatide

Phase 3

TAKEDA PHARMACEUTICAL CO LTD (TAK)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

1 competitor in Anemia

INCYINCB000928

Phase 2

View Full Landscape

Drug Information

Target Indication

Anemia

Clinical Trial

NCT00314795

Last updated: 9/6/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMAPending

Omontys

treatment of symptomatic anaemia associated with chronic kidney disease (CKD)

Conditional

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

TAK

TAKEDA PHARMACEUTICAL CO LTD

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

REPLAGALPhase 3

Fabry Disease

Alogliptin and pioglitazonePhase 3

Type 2 Diabetes Mellitus

HYQVIAPhase 3

Primary Immunodeficiency Diseases (PID)

IGSC 20% infusionPhase 3

Primary Immunodeficiency Disease

Azilsartan medoxomil, with or without chlorthalidone and other non-angiotensin II receptor blocker antihypertensive medications.Phase 3

Hypertension

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts